ATE442379T1 - Bildgebende agentien auf basis bizyklischer peptide - Google Patents

Bildgebende agentien auf basis bizyklischer peptide

Info

Publication number
ATE442379T1
ATE442379T1 AT04743485T AT04743485T ATE442379T1 AT E442379 T1 ATE442379 T1 AT E442379T1 AT 04743485 T AT04743485 T AT 04743485T AT 04743485 T AT04743485 T AT 04743485T AT E442379 T1 ATE442379 T1 AT E442379T1
Authority
AT
Austria
Prior art keywords
bizyclic
peptides
imaging agents
agents based
compounds
Prior art date
Application number
AT04743485T
Other languages
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE442379T1 publication Critical patent/ATE442379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Light Receiving Elements (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04743485T 2003-07-30 2004-07-21 Bildgebende agentien auf basis bizyklischer peptide ATE442379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317815.9A GB0317815D0 (en) 2003-07-30 2003-07-30 Imaging agents
PCT/GB2004/003150 WO2005012335A1 (en) 2003-07-30 2004-07-21 Imaging agents

Publications (1)

Publication Number Publication Date
ATE442379T1 true ATE442379T1 (de) 2009-09-15

Family

ID=27799463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743485T ATE442379T1 (de) 2003-07-30 2004-07-21 Bildgebende agentien auf basis bizyklischer peptide

Country Status (23)

Country Link
US (2) US7410943B2 (de)
EP (1) EP1648925B1 (de)
JP (1) JP4625002B2 (de)
KR (1) KR101153529B1 (de)
CN (1) CN1829735B (de)
AT (1) ATE442379T1 (de)
BR (1) BRPI0412986A (de)
CA (1) CA2533321C (de)
CY (1) CY1109522T1 (de)
DE (1) DE602004023092D1 (de)
DK (1) DK1648925T3 (de)
ES (1) ES2332722T3 (de)
GB (1) GB0317815D0 (de)
HU (1) HUP0600230A3 (de)
IL (1) IL173029A0 (de)
MX (1) MXPA06001090A (de)
NO (1) NO20060825L (de)
NZ (1) NZ544583A (de)
PL (2) PL1648925T3 (de)
PT (1) PT1648925E (de)
RU (2) RU2355702C2 (de)
SI (1) SI1648925T1 (de)
WO (1) WO2005012335A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
CN1925875A (zh) 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
AU2005254915B2 (en) * 2004-06-16 2011-10-13 Ge Healthcare As Peptide-based compounds
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
AU2005307195A1 (en) 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2007122488A2 (en) * 2006-04-20 2007-11-01 Hammersmith Imanet Limited Radiofluorinated compounds and their preparation
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
GB0722650D0 (en) 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
US8415510B2 (en) * 2008-02-28 2013-04-09 Ge Healthcare Limited Synthesis of a PEG-6 moiety from commercial low-cost chemicals
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 a-2-알파 수용체 길항제와 속도 조절제의 조합물
EP2376100B1 (de) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20120229804A1 (en) 2009-12-21 2012-09-13 Medi-Physics, Inc. Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f- ion
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
SI2621496T2 (sl) 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその製剤
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201511036D0 (en) 2015-06-23 2015-08-05 Guy S And St Thomas Hospital Nhs Foundation Trust Imaging method
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774378B2 (ja) * 1991-02-08 1998-07-09 ダイアテク,インコーポレイテッド 映像用テクネチウム−99m標識化ポリペプチド
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP5043271B2 (ja) * 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
WO2002020610A2 (en) * 2000-09-07 2002-03-14 Biosynthema Inc. Conformationally constrained labeled peptides for imaging and therapy
IL141276A0 (en) * 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
CN1622830A (zh) 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Also Published As

Publication number Publication date
ES2332722T3 (es) 2010-02-11
IL173029A0 (en) 2006-06-11
HK1097278A1 (en) 2007-06-22
DK1648925T3 (da) 2010-01-04
KR101153529B1 (ko) 2012-06-11
US20060193773A1 (en) 2006-08-31
US7410943B2 (en) 2008-08-12
US7811551B2 (en) 2010-10-12
PT1648925E (pt) 2009-12-10
DE602004023092D1 (de) 2009-10-22
NZ544583A (en) 2009-12-24
RU2009105640A (ru) 2010-08-27
HUP0600230A3 (en) 2009-09-28
RU2355702C2 (ru) 2009-05-20
CA2533321A1 (en) 2005-02-10
CN1829735B (zh) 2010-05-26
CN1829735A (zh) 2006-09-06
KR20060090795A (ko) 2006-08-16
US20080267881A1 (en) 2008-10-30
JP2007523880A (ja) 2007-08-23
CA2533321C (en) 2012-09-18
PL210122B1 (pl) 2011-12-30
HUP0600230A2 (en) 2007-01-29
NO20060825L (no) 2006-03-29
RU2006102324A (ru) 2007-09-20
PL379705A1 (pl) 2006-11-13
BRPI0412986A (pt) 2006-10-03
PL1648925T3 (pl) 2010-02-26
MXPA06001090A (es) 2006-04-24
EP1648925B1 (de) 2009-09-09
GB0317815D0 (en) 2003-09-03
CY1109522T1 (el) 2014-08-13
JP4625002B2 (ja) 2011-02-02
SI1648925T1 (sl) 2010-01-29
EP1648925A1 (de) 2006-04-26
WO2005012335A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
DE602004023092D1 (de) Bildgebende agentien auf basis bizyklischer peptide
ATE519776T1 (de) Peptidische verbindungen
MXPA04000173A (es) Compuestos basados en peptidos.
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
NO20024932D0 (no) Kontrastmiddel
NO20054116D0 (no) Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
EP1178988A4 (de) Verbindungen und therapeutische methoden
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
DE60217854D1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
DE602004031617D1 (de) Fluoresceinmarkierte peptide
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
ATE425770T1 (de) Kontrastmittel
DE602004029016D1 (de) Stq-peptide
PL2101826T3 (pl) Znakowane izotopowo związki na bazie peptydów i ich zastosowania
TR200103690T2 (tr) IL-8 reseptör antagonistleri
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648925

Country of ref document: EP